Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 71.45% is in line with its 5-year average of 68.60%, near the high end of its 5-year range (62.69%–72.80%).
0.12% above its 12-month average of 71.37%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 72.80%.
GROSS MARGIN
71.45%
GROSS MARGIN AVG TTM
71.37%
GROSS MARGIN AVG 3Y
69.41%
GROSS MARGIN AVG 5Y
68.60%
GROSS MARGIN AVG 10Y
70.51%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.12%
CURRENT VS 3Y AVG
+2.94%
CURRENT VS 5Y AVG
+4.16%
CURRENT VS 10Y AVG
+1.34%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+72.67%
vs the sector median at left
iRhythm Technologies, Inc.
Market Cap
$3.52B
Gross Margin
71.45%
TTM Avg
71.37%
3Y Avg
69.41%
5Y Avg
68.60%
Market Cap
$3.54B
Gross Margin
66.09%
TTM Avg
33.05%
3Y Avg
41.52%
5Y Avg
61.02%
Market Cap
$3.48B
Gross Margin
-43.89%
TTM Avg
0.67%
3Y Avg
45.02%
5Y Avg
61.14%
Market Cap
$3.57B
Gross Margin
98.25%
TTM Avg
98.17%
3Y Avg
99.09%
5Y Avg
95.85%
Market Cap
$3.44B
Gross Margin
-360.00%
TTM Avg
-180.00%
3Y Avg
-491.57%
5Y Avg
-334.18%
Market Cap
$3.64B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.38B
Gross Margin
91.13%
TTM Avg
91.57%
3Y Avg
93.72%
5Y Avg
94.38%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iRhythm Technologies, Inc. (IRTC) | $3.52B | 71.45% | 71.37% | 69.41% | 68.60% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | 66.09% | 33.05% | 41.52% | 61.02% |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 72.09% | 68.25% | 67.74% | 66.97% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -43.89% | 0.67% | 45.02% | 61.14% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | 98.25% | 98.17% | 99.09% | 95.85% |
| Celcuity Inc. (CELC)vs › | $3.47B | 0.00% | 0.00% | 0.00% | 0.00% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -360.00% | -180.00% | -491.57% | -334.18% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | 0.00% | 0.00% | 0.00% | 0.00% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 91.13% | 91.57% | 93.72% | 94.38% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
71.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 72.80% |
| 2026-03-31 | 70.89% |
| 2025-12-31 | 70.88% |
| 2025-09-30 | 71.09% |
| 2025-06-30 | 71.17% |
| 2025-03-31 | 68.83% |
| 2024-12-31 | 70.02% |
| 2024-09-30 | 68.78% |
| 2024-06-30 | 69.89% |
| 2024-03-31 | 66.34% |
| 2023-12-31 | 65.98% |
| 2023-09-30 | 66.19% |
| 2023-06-30 | 69.46% |
| 2023-03-31 | 67.91% |
| 2022-12-31 | 69.89% |
| 2022-09-30 | 68.28% |
| 2022-06-30 | 68.83% |
| 2022-03-31 | 66.85% |
| 2021-12-31 | 62.69% |
| 2021-09-30 | 65.72% |
| 2021-06-30 | 68.02% |
| 2021-03-31 | 68.43% |
| 2020-12-31 | 73.99% |
| 2020-09-30 | 74.66% |
| 2020-06-30 | 69.57% |
| 2020-03-31 | 74.72% |
| 2019-12-31 | 76.46% |
| 2019-09-30 | 74.79% |
| 2019-06-30 | 75.19% |
| 2019-03-31 | 75.64% |
| 2018-12-31 | 75.60% |
| 2018-09-30 | 74.11% |
| 2018-06-30 | 73.24% |
| 2018-03-31 | 71.83% |
| 2017-12-31 | 72.66% |
| 2017-09-30 | 72.36% |
| 2017-06-30 | 71.73% |
| 2017-03-31 | 70.44% |
| 2016-12-31 | 69.07% |
| 2016-09-30 | 68.52% |
| 2016-06-30 | 67.23% |
| 2016-03-31 | 63.75% |
| 2015-12-31 | 61.66% |
| 2015-09-30 | 59.89% |
| 2015-06-30 | 57.40% |
| 2015-03-31 | 57.40% |
| 2014-12-31 | 53.28% |
